Silab says it has decrypted, in vivo, the molecular signature of atopic dermatitis. The study, conducted in partnership with Prof. Michel Manfait, was published in the journal Experimental Dermatology. Silab's Ad-Resyl, is a purified natural active ingredient that has been specifically developed to prevent the clinical signs of atopic dermatitis and prolong periods of remission following corticosteroid therapy, according to the company.


According to Silab, the research studies conducted reveal for the first time in vivo, and non-invasively, the molecular signature of atopic skins that reflects changes in the lipid matrix (organization and conformation) and hydration (total and bound water content). This study was carried out using confocal Raman microspectroscopy in vivo in collaboration with Manfait and his team.


“The equipment we used has a flexible probe which enables molecular descriptors of the skin to be explored in vivo, whatever area of skin is studied. Highly precise, it also generates masses of data. Expertise of a specific protocol that enables spectra to be sorted and processed is indispensable in order to obtain the necessary quality to exploit them statistically,” explained Raoul Vyumvuhore, biophysics laboratory manager, Silab.